Polyrizon prepares for allergy blocker trial with strategic manufacturing partnership

Polyrizon Ltd., a biotech company known for its cutting-edge nasal hydrogel technology, has solidified its preparations for the anticipated 2025 allergy blocker trial by entering into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S. This partnership ensures a consistent and high-quality supply of clinical trial material (CTM) necessary for evaluating PL-14, the company’s innovative allergy prevention solution.

The collaboration provides Polyrizon with a strategic advantage, as Eurofins CDMO operates as a Good Manufacturing Practice (GMP) facility compliant with both USA and European standards. The manufacturing site not only guarantees the timely production of CTM for the clinical trial but also supports future scalability, a critical factor in commercialization.

Nasal Hydrogel Technology: Polyrizon’s Unique Approach

At the heart of Polyrizon’s innovation lies its proprietary Capture and Contain (C&C) hydrogel technology. This platform, designed as a nasal spray, forms a thin hydrogel barrier within the nasal cavity. The barrier functions as a “biological mask,” effectively blocking allergens and viruses from contacting nasal epithelial tissues.

PL-14 represents a significant step forward in the application of nasal hydrogel technology, offering a revolutionary way to manage allergies. In addition to its focus on PL-14, Polyrizon continues to develop the Trap and Target (T&T) technology, which is geared toward the nasal delivery of active pharmaceutical ingredients (APIs). This initiative, while in the early stages of pre-clinical development, showcases the company’s commitment to pushing the boundaries of intranasal therapies.

Scaling Up for Clinical Trial Material and Beyond

The partnership with Eurofins CDMO is pivotal not only for the upcoming allergy blocker trial but also for Polyrizon’s long-term vision. The GMP-certified manufacturing facility is equipped with large-scale production capabilities, ensuring that the supply of clinical trial material remains reliable and scalable. This capability is essential as the company transitions from clinical testing to broader commercialization efforts.

Polyrizon’s CEO, Tomer Izraeli, emphasized the importance of this manufacturing agreement, calling it a cornerstone in the preparation for the 2025 trial. He reiterated the company’s dedication to developing allergy prevention solutions that address unmet medical needs, highlighting the transformative potential of PL-14.

Allergy Blocker Trial: A Step Toward Market Leadership

The 2025 allergy blocker trial will evaluate PL-14’s safety and efficacy, marking a critical milestone in Polyrizon’s journey. The data generated from this study will form the foundation for regulatory submissions and future market launches. By investing in robust partnerships and innovative research, Polyrizon is positioning itself as a leader in the field of nasal hydrogel technology and allergy prevention solutions.

This development reflects the company’s mission to enhance health outcomes through targeted and effective solutions. With its proprietary technologies, Polyrizon is poised to revolutionize the way allergies and respiratory health issues are addressed, offering patients improved protection and quality of life.